Abstract
Background: Second generation direct acting-antivirals are safe and effective treatments for chronic hepatitis C patients.
Objective: We aimed to conduct a systematic review of case reports and case series to evaluate the safety of the drugs, highlighting a compilation of AE not previously reported in other reviews. Methods: The search was performed in four electronic databases and included only case reports and case series that evaluated interferon-free therapies and provided safety outcomes. Results: Initially 1,235 records were retrieved, and after screening 30 studies were included in the analysis (23 case reports and 7 case series). A total of 39 patients were included, receiving eight different interferon-free treatments. Nineteen patients discontinued treatment (only 8 of these achieved treatment response). Other 19 patients achieved SVR without discontinuation. Rare adverse events were observed, including breast hypertrophy, retinopathy and drug-induced infection. Some patients were in an advanced stage of the disease, and were therefore unable to withstand treatment due to the appearance of complications. Conclusion: In this sense, it is important to monitor the use of these drugs that can favor the appearance of serious AE. (PROSPERO registration number CRD42016051680).Keywords: Interferon-free, hepatitis C, case report, systematic review, case series, treatment.
Graphical Abstract
[1]
World Health Organization (WHO). Hepatitis C Fact Sheet
No 164. WHO Web site. 2017. Available From. http: //www.who.int/mediacentre/factsheets/fs164/en/ Accessed
on: May 02, 2017.
[2]
Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of interferon-free therapies for chronic hepatitis C: a systematic review of all randomized clinical trials. Clin Drug Investig 2017; 37: 635-46.
[3]
AASLD-IDSA. Recommendations for testing, managing,
and treating hepatitis C. Available From http:
//www.hcvguidelinesorg 2016 Accesses on: May 02, 2017.
[4]
Ferreira VL, Assis Jarek NA, Tonin FS, Borba HHL, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther 2016; 41: 478-85.
[5]
European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-36.
[6]
(WHO) WHO. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection Updated
version, April 2016.
[7]
Ferreira VL, Assis Jarek NA, Tonin FS, et al. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. J Gastroenterol Hepatol 2017; 32: 749-55.
[8]
FakhriRavari A. Malakouti M, Brady R. Interferon-Free treatments for chronic hepatitis C genotype 1 infection. J Clin Transl Hepatol 2016; 4: 97-112.
[9]
Danish SH, Reza Z, Sohail AA. Case reports and their importance in medical literature. JPMA J Pakistan Med Ass 2017; 67: 451-3.
[10]
Nayak BK. The significance of case reports in biomedical publication. Indian J Ophthalmol 2010; 58: 363-4.
[11]
Ferreira VL, Leonart LP, Tonin FS, Borba HHL, Pontarolo R. Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: a systematic review and meta-analysis of observational cohort studies. Clin Drug Investig 2018; 38: 389-400.
[12]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med 2009; 6(7)e1000100
[13]
Higgins JPT, Green S. Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0: Cochrane 2011.
[14]
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
[15]
Bonacci M, Londoño MC, Esforzado N, Forns X, Sotoca JM, Campistol JM. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: Viral eradication and removal from the liver transplant waiting list. Transpl Int 2015; 28: 1345-9.
[16]
Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 2015; 35: 2222-7.
[17]
Chin-Loy K, Galaydh F, Shaikh S. Retinopathy and uveitis associated with sofosbuvir therapy for chronic hepatitis C infection. Cureus 2016; 8e597
[18]
Debes JD, Ricci P. Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir. Dig Liver Dis 2015; 47: 1091-2.
[19]
Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology 2015; 61: 400-1.
[20]
Gentili M, Magni C, Carnovale C, et al. Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina. Breast J 2016; 22: 708-9.
[21]
Hasin Y, Shteingart S, Dahari H, et al. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report. World J Hepatol 2016; 8: 858-62.
[22]
Helmers RA, Byrne TJ, Wesselius LJ, Leslie KO. Serious pulmonary toxicity secondary to novel hepatitis C antiviral therapy in a liver transplant recipient. Mayo Clin Proc 2015; 90: 1294-7.
[23]
Hoogeveen RC, Sonnen MPAM, Sankatsing SUC. Visual hallucinations during hepatitis C treatment with sofosbuvir and simeprevir: a case report Infect Dis Clin Pract 2016; 24: E65-E.
[24]
Izzo I, Zanotti P, Chirico C, et al. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C. Infection 2016; 44: 811-2.
[25]
Kamada T, Furuta K, Tomioka H. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report. Respir Investig 2016; 54: 207-10.
[26]
Kawaoka T, Imamura M, Morio K, et al. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. Hepatol Res 2016; 46: 707-12.
[27]
Meissner EG, Nelson A, Marti M, Masur H, Osinusi A, Kottilil S. Sustained virologic response for chronic hepatitis C infection after 27 days of treatment with sofosbuvir and ribavirin. Open Forum Infect Dis 2014; 1: 013.
[28]
Ohta Y, Kanda T, Katsuno T, et al. Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report. BMC Gastroenterol 2016; 16: 66.
[29]
Ou P, Fang Z, Chen J. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report. Clin Res Hepatol Gastroenterol 2017; 41: e17-8.
[30]
Ramadori G, Bosio P, Moriconi F, Malik IA. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy. Aliment Pharmacol Ther 2018; 18: 257.
[31]
Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 2015; 62: 234-7.
[32]
Safadi R, Noviello S, Boparai N, McPhee F. Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir. Clin Case Rep 2016; 4: 653-6.
[33]
Syal G, Heldenbrand SD, Duarte-Rojo A. Seizures as a potential complication of treatment with simeprevir and sofosbuvir. Am J Ther 2016; 23: e570-1.
[34]
Taibi C, Tempestilli M, D’Avolio A. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. J Clin Pharm Ther 2017; 42: 621-3.
[35]
Weng Q, Li X, Ren H, et al. Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature. Oncotarget 2017; 8: 22299-303.
[36]
Wu SYS, Faire B, Gane E. Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK (R)) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction. Case Rep Intern Med 2017.4895736
[37]
Celen MK, Akdemir I, Tekin R, Bayan K, Ayaz C. Elbasvir/grazoprevir experience - a new glance at HCV treatment: case report. Viral Hepatit Dergisi 2017; 23: 34-6.
[38]
Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016; 64: 234-8.
[39]
Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med 2015; 373: 1886-8.
[40]
Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond) 2015; 47: 924-9.
[41]
Krastev Z, Jelev D, Antonov K, et al. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. World J Gastroenterol 2016; 22: 2630-5.
[42]
Renard S, Borentain P, Salaun E, et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest 2016; 149: e69-73.
[43]
Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149: 1378-80.e1.
[44]
Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2015; 60: 1031-5.
[45]
Rutherford A, Dienstag JL. Viral Hepatitis. In: Greenberger NJ, Blumberg RS, Burakoff R, Eds. Current Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy. 3rd ed. New York: McGraw-Hill Education 2016.
[46]
D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol 2017; 24: 31-7.
[47]
Collins LF, Chan A, Zheng J, et al. Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV Infection. Open Forum Infect Dis 2018; 5: ofx264-1-.
[48]
Sofosbuvir (Rx). Available From https: //reference. medscape.com/drug/sovaldi-sofosbuvir-999890#4 Medscape
2018. Accessed on May 18, 2018.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Delivery
Related Books
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
New Avenues in Drug Discovery and Bioactive Natural Products
Practice and Re-Emergence of Herbal Medicine
Methods for Preclinical Evaluation of Bioactive Natural Products
Article Metrics
52
2